| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 10/21/2004 | WO2003045228A3 Methods for treating autoimmune disorders, and reagents related thereto |
| 10/21/2004 | WO2003043631A3 Method for identification of tumor targeting enzymes |
| 10/21/2004 | WO2003027266A3 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| 10/21/2004 | WO2003026490A3 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules |
| 10/21/2004 | WO2003024392A3 Compositions and methods for the diagnosis and treatment of tumor |
| 10/21/2004 | WO1995018619A9 Bicyclic fibrinogen antagonists |
| 10/21/2004 | US20040210950 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (CALSARCINS) |
| 10/21/2004 | US20040210080 3-(oxo, oxime, hydrazone, or alkylidene)-fluorene derivatives; can be synergistically combined with other anticarcinogenic, anticholesterol, anxiolytic agents, antidepressants or enzyme inhibitors; bone disorders |
| 10/21/2004 | US20040210079 selective monoamine oxidase B inhibitors; neurodegenerative diseases; Alzheimer's Disease |
| 10/21/2004 | US20040210052 Efficient synthesis of 5-heteroatom-containing-pyrazoles |
| 10/21/2004 | US20040210042 Polypeptides relating to signal transfer of advanced glycation end product receptor |
| 10/21/2004 | US20040210038 Il-1 eta DNA and polypeptides |
| 10/21/2004 | US20040209957 A 5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, acid ester, sulfonic acid or amide derivatives, for treating Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, stroke |
| 10/21/2004 | US20040209938 Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them |
| 10/21/2004 | US20040209935 Pyrazole-derived kinase inhibitors and uses thereof |
| 10/21/2004 | US20040209934 Protein phosphate inhibitors |
| 10/21/2004 | US20040209922 Pyridine matrix metalloproteinase inhibitors |
| 10/21/2004 | US20040209914 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 10/21/2004 | US20040209901 substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors. |
| 10/21/2004 | US20040209899 A2B adenosine receptor antagonists |
| 10/21/2004 | US20040209894 e.g., 1-(4-chloroanilino)-4-[2-(pyridin-3-yl)-ethyl]-isoquinoline and 5-[4-(tert-butyl)-anilino]-8-[(6-methoxy-pyridin-3-yl)-methyl]-[1,6]naphthyridine |
| 10/21/2004 | US20040209885 Combination therapy for the treatment of heart failure |
| 10/21/2004 | US20040209883 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors |
| 10/21/2004 | US20040209879 Piperidinyl derivates as modulators of chemokine receptor activity |
| 10/21/2004 | US20040209874 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
| 10/21/2004 | US20040209870 contain 5-HT ligands used to treat central nervous system disorders |
| 10/21/2004 | US20040209868 Substituted indoles |
| 10/21/2004 | US20040209867 for treatment of disorders (sleeping, feeding) relating to or affected by the 5-HT6 receptor; serotonin receptor antagonists |
| 10/21/2004 | US20040209866 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders |
| 10/21/2004 | US20040209861 Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease |
| 10/21/2004 | US20040209843 addtion of a cyclodextrin compound increases the water solubility; storage stable solution; immediately treating symptoms of acute phases of myocardial or a cerebral infarction |
| 10/21/2004 | US20040209822 Novel compounds |
| 10/21/2004 | US20040209817 Methods and compositions for the treatment of peripheral artery disease |
| 10/21/2004 | US20040209816 Treatment for diabetes |
| 10/21/2004 | US20040209813 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases |
| 10/21/2004 | US20040209805 such as fibrosis via activin antagonist (fullistatin); kits; gene therapy; treating inflammatory bowel disease and crohn's disease |
| 10/21/2004 | US20040209799 comprises inhibitors (cytokines) of janus kinases (JAK)/signal transducers and activators of transcription (STAT) other than debromohymenialdisine and hymensialdisine; gene expression inhibition; bioassay, immunoassay, drug screening; for treatment of degenerative joint diseases such as osteoarthritis |
| 10/21/2004 | US20040209342 Comprises nucleotide sequences coding hydrolase for use in identifying modulators for treatment of diabetes and inflammatory diseases |
| 10/21/2004 | US20040209288 Using adjustments in leukotriene biosynthetic profile as tool to diagnosis and treat cardiovasular disorders |
| 10/21/2004 | US20040209271 Dna providing system |
| 10/21/2004 | US20040209264 Comprises nucleotide sequences coding daugther of legless protein for use in identifying modulator for tissue regeneration and repair and the treatment of blood disorders |
| 10/21/2004 | US20040208944 Compositions and methods against inflammatory processes |
| 10/21/2004 | US20040208923 administering a therapeutically effective amount of a pharmacologic agent that enhances learning or conditioning within 24 hours prior to conducting session of psychotherapy |
| 10/21/2004 | US20040208896 Immunotherapy for humans |
| 10/21/2004 | US20040208889 Pharmaceutical use for secreted bacterial effector proteins |
| 10/21/2004 | US20040208861 Stromal cell use |
| 10/21/2004 | US20040208859 Bile acid absorbent/adsorbent |
| 10/21/2004 | US20040208857 Producing a donor-specific immunotolerance against transplanted tissue by administering embryonic stem cell-like cell lines (ECL) obtained from blastocysts and are transfected with genetic material of the donor, which codes for the major histocompatibility complex (MHC) haplotypes |
| 10/21/2004 | US20040208845 Delivering structurally reinforcing agents into a ventricle to increase compliance; prevention of remodeling and thinning of infarct zone by crosslinking collagen; pro-fibroblastic, antiischemic and angiogenic agents |
| 10/21/2004 | CA2521830A1 Heteroaromatic pentacyclic compound and medicinal use thereof |
| 10/21/2004 | CA2519882A1 Novel crystals of fluorobenzamide derivative |
| 10/20/2004 | EP1469077A1 Cell-specific expression/replication vector |
| 10/20/2004 | EP1468998A1 Crystalline monohydrate of Tiotropium bromide and process for its preparation |
| 10/20/2004 | EP1468997A2 Polymorphous forms of rosiglitazone maleate |
| 10/20/2004 | EP1468995A1 MPTP affinity labels |
| 10/20/2004 | EP1468991A1 Imides as PDE III, PDE IV and TNF inhibitors |
| 10/20/2004 | EP1468990A1 Piperazine derivative |
| 10/20/2004 | EP1468684A1 Sigma receptor binder containing indanone derivative |
| 10/20/2004 | EP1468682A1 Therapeutic combinations comprising amlodipine and atorvastatin |
| 10/20/2004 | EP1468680A2 Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
| 10/20/2004 | EP1468110A2 Molecular signatures of commonly fatal carcinomas |
| 10/20/2004 | EP1468098A2 Method of inhibiting pathogenicity of infectious agents |
| 10/20/2004 | EP1468091A2 Transmembrane protein |
| 10/20/2004 | EP1468019A2 Secreted protein |
| 10/20/2004 | EP1468018A2 Leptin proteins |
| 10/20/2004 | EP1468017A1 A complex of a human foxc2 protein and a foxc2-interacting protein |
| 10/20/2004 | EP1468008A2 MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) PROMOTER POLYMORPHISM IN INFLAMMATORY DISEASE |
| 10/20/2004 | EP1468003A2 Phosphinic pseudo-peptide derivatives |
| 10/20/2004 | EP1467999A1 Oxothieno[3,2-b]pyridinecarboxamides as antiviral agents |
| 10/20/2004 | EP1467998A1 Tetracyclic heterocompounds as estrogen receptor modulators |
| 10/20/2004 | EP1467997A1 Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group |
| 10/20/2004 | EP1467996A1 Pyrimidotriazines as phosphatase inhibitors |
| 10/20/2004 | EP1467995A2 Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use |
| 10/20/2004 | EP1467994A1 Pteridine derivatives, method for the production thereof, and use thereof |
| 10/20/2004 | EP1467989A1 Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatitis c virus infection |
| 10/20/2004 | EP1467982A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof |
| 10/20/2004 | EP1467979A2 FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION |
| 10/20/2004 | EP1467978A1 Pancreatic lipase inhibitor compounds, their synthesis and use |
| 10/20/2004 | EP1467974A1 Benzimidazole derivatives and their use as gnrh antagonists |
| 10/20/2004 | EP1467972A1 Indazole compounds useful as protein kinase inhibitors |
| 10/20/2004 | EP1467970A1 Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors |
| 10/20/2004 | EP1467968A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 10/20/2004 | EP1467965A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 10/20/2004 | EP1467768A1 Increasing electro-gene transfer of nucleic acid molecules into host tissue |
| 10/20/2004 | EP1467765A2 Combination therapy for the treatment of bacterial infections |
| 10/20/2004 | EP1467759A2 Compositions and methods related to tim-3, a th1-specific cell surface molecule |
| 10/20/2004 | EP1467758A2 Methods for preparing immunoconjugates |
| 10/20/2004 | EP1467757A2 Use of antibodies against the muc18 antigen |
| 10/20/2004 | EP1467756A2 Methods for using anti-muc18 antibodies |
| 10/20/2004 | EP1467752A1 HUMAN MAST CELL−EXPRESSED MEMBRANE PROTEINS |
| 10/20/2004 | EP1467750A1 Orodispersible pharmaceutical composition comprising perindopril |
| 10/20/2004 | EP1467749A1 Thrombin derived peptides for promoting cardiac tissue repair |
| 10/20/2004 | EP1467745A2 Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders |
| 10/20/2004 | EP1467741A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 10/20/2004 | EP1467740A1 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases |
| 10/20/2004 | EP1467733A1 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| 10/20/2004 | EP1467732A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 10/20/2004 | EP1467731A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 10/20/2004 | EP1467728A1 Pharmaceutical compositions comprising valsartan and nep inhibitors |
| 10/20/2004 | EP1467721A2 Substituted amine derivatives and their use for the treatment of angiogenesis |